Is RANI or EPRX more profitable?

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -104.60% -65.17% Eupraxia Pharmaceuticals N/A -63.97% -43.32%

Does the media prefer RANI or FHTX?

In the previous week, Rani Therapeutics had 6 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 7 mentions for Rani Therapeutics and 1 mentions for Foghorn Therapeutics. Rani Therapeutics' average media sentiment score of 0.31 beat Foghorn Therapeutics' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CMPX or RANI more profitable?

Compass Therapeutics' return on equity of -38.71% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -38.71% -34.72% Rani Therapeutics N/A -104.60% -65.17%

Is RANI or LRMR more profitable?

Rani Therapeutics' return on equity of -104.60% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -104.60% -65.17% Larimar Therapeutics N/A -137.39% -97.65%

Does the media favor RANI or LRMR?

In the previous week, Rani Therapeutics had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 7 mentions for Rani Therapeutics and 1 mentions for Larimar Therapeutics. Rani Therapeutics' average media sentiment score of 0.31 beat Larimar Therapeutics' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RANI or PRTC?

Rani Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 896.58%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Rani Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, RANI or PRTC?

Rani Therapeutics has higher earnings, but lower revenue than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rani Therapeutics $1.63M 75.09 -$29.67M -$0.27 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is RANI or PRTC more profitable?

PureTech Health's return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -104.60% -65.17% PureTech Health N/A N/A N/A

Does the media prefer RANI or PRTC?

In the previous week, Rani Therapeutics had 6 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Rani Therapeutics and 1 mentions for PureTech Health. Rani Therapeutics' average media sentiment score of 0.31 beat PureTech Health's score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Rani Therapeutics (RANI) Competitors

$0.88 0.00 (-0.23%)

As of 03:44 PM Eastern

Compare

RANI vs. EPRX, FHTX, CMPX, LRMR, and PRTC

Should you buy Rani Therapeutics stock or one of its competitors? Rani Therapeutics's main competitors and comparable companies include Eupraxia Pharmaceuticals (EPRX), Foghorn Therapeutics (FHTX), Compass Therapeutics (CMPX), Larimar Therapeutics (LRMR), and PureTech Health (PRTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rani Therapeutics compare to Eupraxia Pharmaceuticals?

Rani Therapeutics (NASDAQ:RANI) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

In the previous week, Rani Therapeutics had 7 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 7 mentions for Rani Therapeutics and 0 mentions for Eupraxia Pharmaceuticals. Rani Therapeutics' average media sentiment score of 0.31 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Rani Therapeutics	Neutral
Eupraxia Pharmaceuticals	Neutral

30.2% of Rani Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%

Rani Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 896.58%. Eupraxia Pharmaceuticals has a consensus price target of $18.00, suggesting a potential upside of 148.10%. Given Rani Therapeutics' higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Rani Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Rani Therapeutics has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	75.09	-$29.67M	-$0.27	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A

Summary

Rani Therapeutics beats Eupraxia Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Rani Therapeutics compare to Foghorn Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Rani Therapeutics currently has a consensus price target of $8.75, indicating a potential upside of 896.58%. Foghorn Therapeutics has a consensus price target of $11.43, indicating a potential upside of 66.96%. Given Rani Therapeutics' higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Rani Therapeutics had 6 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 7 mentions for Rani Therapeutics and 1 mentions for Foghorn Therapeutics. Rani Therapeutics' average media sentiment score of 0.31 beat Foghorn Therapeutics' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rani Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

Rani Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, meaning that its stock price is 189% more volatile than the broader market.

Rani Therapeutics has higher earnings, but lower revenue than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	75.09	-$29.67M	-$0.27	N/A
Foghorn Therapeutics	$36.74M	11.06	-$74.28M	-$0.98	N/A

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Rani Therapeutics beats Foghorn Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Rani Therapeutics compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Compass Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Rani Therapeutics had 7 more articles in the media than Compass Therapeutics. MarketBeat recorded 7 mentions for Rani Therapeutics and 0 mentions for Compass Therapeutics. Rani Therapeutics' average media sentiment score of 0.31 beat Compass Therapeutics' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Compass Therapeutics	Neutral
Rani Therapeutics	Neutral

Rani Therapeutics has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	509.55	-$66.49M	-$0.40	N/A
Rani Therapeutics	$1.63M	75.09	-$29.67M	-$0.27	N/A

Compass Therapeutics currently has a consensus target price of $11.77, suggesting a potential upside of 389.37%. Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 896.58%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Compass Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Compass Therapeutics' return on equity of -38.71% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
Rani Therapeutics	N/A	-104.60%	-65.17%

Summary

Compass Therapeutics and Rani Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Rani Therapeutics compare to Larimar Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Rani Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Rani Therapeutics' return on equity of -104.60% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
Larimar Therapeutics	N/A	-137.39%	-97.65%

In the previous week, Rani Therapeutics had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 7 mentions for Rani Therapeutics and 1 mentions for Larimar Therapeutics. Rani Therapeutics' average media sentiment score of 0.31 beat Larimar Therapeutics' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by company insiders. Comparatively, 4.0% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rani Therapeutics has higher revenue and earnings than Larimar Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	75.09	-$29.67M	-$0.27	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

Rani Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 896.58%. Larimar Therapeutics has a consensus target price of $11.67, suggesting a potential upside of 187.00%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Larimar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Summary

Rani Therapeutics beats Larimar Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to PureTech Health?

Rani Therapeutics (NASDAQ:RANI) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

PureTech Health's return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
PureTech Health	N/A	N/A	N/A

Rani Therapeutics has higher earnings, but lower revenue than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	75.09	-$29.67M	-$0.27	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Rani Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Rani Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 896.58%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Rani Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Rani Therapeutics had 6 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Rani Therapeutics and 1 mentions for PureTech Health. Rani Therapeutics' average media sentiment score of 0.31 beat PureTech Health's score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by company insiders. Comparatively, 5.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Rani Therapeutics beats PureTech Health on 8 of the 13 factors compared between the two stocks.

Get Rani Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RANI vs. The Competition

Export

Metric	Rani Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$122.39M	$3.99B	$7.29B	$12.73B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-3.25	11.76	271.37	24.13
Price / Sales	75.09	1,299.21	605.97	78.27
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	2.58	17.27	11.19	6.40
Net Income	-$29.67M	-$22.72M	$3.46B	$348.39M
7 Day Performance	10.32%	2.96%	2.07%	1.09%
1 Month Performance	3.18%	9.80%	7.40%	5.27%
1 Year Performance	40.61%	54.94%	24.84%	16.29%

Rani Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RANI Rani Therapeutics	3.6642 of 5 stars	$0.88 -0.2%	$8.75 +896.6%	+40.9%	$122.39M	$1.63M	N/A	110	Analyst Forecast
EPRX Eupraxia Pharmaceuticals	N/A	$6.70 -0.9%	$18.00 +168.7%	+27.5%	$435.63M	N/A	N/A	29
FHTX Foghorn Therapeutics	1.9493 of 5 stars	$7.17 +2.3%	$11.43 +59.4%	+27.2%	$425.79M	$36.74M	N/A	120	Gap Up
CMPX Compass Therapeutics	1.8321 of 5 stars	$2.36 flat	$11.77 +398.7%	-20.5%	$425.01M	$850K	N/A	20
LRMR Larimar Therapeutics	3.2508 of 5 stars	$4.09 -1.7%	$11.67 +185.2%	+6.9%	$424.88M	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RANI) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rani Therapeutics (RANI) Competitors

RANI vs. EPRX, FHTX, CMPX, LRMR, and PRTC

How does Rani Therapeutics compare to Eupraxia Pharmaceuticals?

Summary

How does Rani Therapeutics compare to Foghorn Therapeutics?

Summary

How does Rani Therapeutics compare to Compass Therapeutics?

Summary

How does Rani Therapeutics compare to Larimar Therapeutics?

Summary

How does Rani Therapeutics compare to PureTech Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rani Therapeutics (RANI) Competitors

RANI vs. EPRX, FHTX, CMPX, LRMR, and PRTC

How does Rani Therapeutics compare to Eupraxia Pharmaceuticals?

Does the media favor RANI or EPRX?

Do insiders and institutionals hold more shares of RANI or EPRX?

Is RANI or EPRX more profitable?

Do analysts prefer RANI or EPRX?

Which has more volatility and risk, RANI or EPRX?

Which has higher valuation and earnings, RANI or EPRX?

Summary

How does Rani Therapeutics compare to Foghorn Therapeutics?

Do analysts prefer RANI or FHTX?

Does the media prefer RANI or FHTX?

Is RANI or FHTX more profitable?

Which has more volatility & risk, RANI or FHTX?

Which has stronger valuation and earnings, RANI or FHTX?

Do institutionals & insiders believe in RANI or FHTX?

Summary

How does Rani Therapeutics compare to Compass Therapeutics?

Which has more risk and volatility, CMPX or RANI?

Do institutionals and insiders hold more shares of CMPX or RANI?

Does the media prefer CMPX or RANI?

Which has better valuation & earnings, CMPX or RANI?

Do analysts prefer CMPX or RANI?

Is CMPX or RANI more profitable?

Summary

How does Rani Therapeutics compare to Larimar Therapeutics?

Which has more volatility & risk, RANI or LRMR?

Is RANI or LRMR more profitable?

Does the media favor RANI or LRMR?

Do institutionals and insiders hold more shares of RANI or LRMR?

Which has better valuation and earnings, RANI or LRMR?

Do analysts recommend RANI or LRMR?

Summary

How does Rani Therapeutics compare to PureTech Health?

Is RANI or PRTC more profitable?

Which has preferable earnings and valuation, RANI or PRTC?

Which has more volatility & risk, RANI or PRTC?

Do analysts recommend RANI or PRTC?

Does the media prefer RANI or PRTC?

Do institutionals & insiders have more ownership in RANI or PRTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools